BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//LifeSci Events - ECPv6.15.11//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:LifeSci Events
X-ORIGINAL-URL:https://lifescievents.com
X-WR-CALDESC:Events for LifeSci Events
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260310T120000
DTEND;TZID=America/New_York:20260310T133000
DTSTAMP:20260416T013631
CREATED:20260224T174311Z
LAST-MODIFIED:20260226T170431Z
UID:2909-1773144000-1773149400@lifescievents.com
SUMMARY:Galectin Therapeutics Virtual KOL Event to Discuss Belapectin Development Program for Treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) Cirrhosis and Portal Hypertension
DESCRIPTION:Please join Galectin Therapeutics for a virtual key opinion leader (KOL) event focused on the unmet need and current treatment landscape for metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. Featured KOLs will include: \n\nNaga P. Chalasani\, MD\, Professor of Gastroenterology and Hepatology\, Adjunct Professor of Anatomy\, Cell Biology and Physiology\, & Director of Terance Kahn Liver Research Program at Indiana University School of Medicine; and\nNaim Alkhouri\, MD\, FAASLD\, DABOM\, Chief Academic Officer at Summit Clinical Research San Antonio\, TX and the Director of the Steatotic Liver Program at North Shore Gastroenterology in Cleveland\, OH\n\nThe event will highlight updated results from Galectin’s NAVIGATE Phase 3 clinical trial evaluating belapectin for the treatment of MASH cirrhosis and portal hypertension. These results reinforce and extend previously reported findings supporting the antifibrotic and disease-modifying potential of belapectin. Belapectin is a complex carbohydrate drug that targets galectin-3\, a critical protein in the pathogenesis of MASH and fibrosis. With no approved therapies to prevent or treat varices in MASH cirrhosis\, belapectin may represent the first potential treatment to address this significant unmet need. \nA live question and answer session will follow the formal presentations. Watch the webcast by clicking this link and logging in with the email address you used to register: https://lifescievents.com/event/jpsl2e8/.
URL:https://lifescievents.com/event/jpsl2e8/
LOCATION:Virtual\, Virtual
ATTACH;FMTTYPE=image/png:https://lifescievents.com/wp-content/uploads/2026/02/Galectin-Banner.png
END:VEVENT
END:VCALENDAR